The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL-6 concentration

Journal of Internal Medicine

Volumn 261, Issue 2, 2007, Pages 138-147

  Mannila, M N ^a   Eriksson, P ^a   Leander, K ^b   Wiman, B ^a   De Faire, U ^a,b   Hamsten, A ^a   Silveira, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Fibrinogen; Haplotypes; Interleukin 6; Myocardial infarction; Pleiotropic effect

Indexed keywords

FIBRINOGEN; INTERLEUKIN 6; LEUCINE; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HAPLOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BASE SEQUENCE; BLOOD COAGULATION; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FIBRINOGEN; HAPLOTYPES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION;

EID: 33846149334     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01749.x     Document Type: Article

References (45)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL. Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002; 12: 317-24.
3. Wassmann S, Stumpf M, Strehlow K et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534-41.
4. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999; 19: 2364-7.
5. Maier W, Altwegg LA, Corti R et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111: 1355-61.
6. Biasucci LM, Vitelli A, Liuzzo G et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-7.
7. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
8. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
9. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-809.
10. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-9.
11. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-5.
12. JP, Park D, Lesty C et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
13. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
14. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
15. Warner D, Mansfield MW, Grant PJ. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. Thromb Haemost 2001; 85: 408-11.
16. Marin F, Corral J, Roldan V et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004; 37: 699-704.
17. Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci U S A 1982; 79: 1530-4.
18. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-6.
19. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-94.
20. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-9.
21. Mannila MN, Eriksson P, Lundman P et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005; 93: 570-7.
22. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood 2005; 106: 4176-83.
23. Leander K, Wiman B, Hallqvist J, Falk G, De Faire U. The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women. J Intern Med 2002; 252: 332-41.
24. Smith GD, Harbord R, Milton J, Ebrahim S, Sterne JA. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005; 25: 2228-33.
25. Mannila MN, Silveira A, Hawe E et al. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study. Thromb Haemost 2004; 92: 1240-9.
26. Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25: 526-32.
27. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583-7.
28. Reuterwall C, Hallqvist J, Ahlbom A et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. J Intern Med 1999; 246: 161-74.
29. Hallqvist J, Lundberg M, Diderichsen F, Ahlbom A. Socioeconomic differences in risk of myocardial infarction 1971-1994 in Sweden: time trends, relative risks and population attributable risks. Int J Epidemiol 1998; 27: 410-5.
30. Vermylen C, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta 1963; 8: 418-24.
31. Jurinke C, van den Boom D, Cantor CR, Koster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2002; 187: 179-92.
32. Raymond M, Rousset F. An exact test for population differentiation. Evolution 1995; 49: 1280-3.
33. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-89.
34. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004; 68: 165-77.
35. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
36. Rinn JL, Snyder M. Sexual dimorphism in mammalian gene expression. Trends Genet 2005; 21: 298-305.
37. Bennet AM, Prince JA, Fei GZ et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003; 171: 359-67.
38. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006; 95: 511-8.
39. Rosengren A, Wallentin L, Simoons M et al. Cardiovascular risk factors and clinical presentation in acute coronary syndromes. Heart 2005; 91: 1141-7.
40. Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect of gender on outcomes of acute coronary syndromes. Am J Cardiol 2003; 91: 1466-9, A6.
41. Yang Q, Tofler GH, Cupples LA et al. A genome-wide search for genes affecting circulating fibrinogen levels in the Framingham Heart Study. Thromb Res 2003; 110: 57-64.
42. Soria JM, Almasy L, Souto JC et al. A genome search for genetic determinants that influence plasma fibrinogen levels. Arterioscler Thromb Vasc Biol 2005; 25: 1287-92.
43. Samnegard A, Silveira A, Lundman P et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005; 258: 411-9.
44. Abildstrom SZ, Rasmussen S, Rosen M, Madsen M. Trends in incidence and case fatality rates of acute myocardial infarction in Denmark and Sweden. Heart 2003; 89: 507-11.
45. Almasy L, MacCluer JW. Association studies of vascular phenotypes: how and why? Arterioscler Thromb Vasc Biol 2002; 22: 1055-7.